nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.0343	0.048	CbGbCtD
Salmeterol—CYP2C8—Trimethadione—epilepsy syndrome	0.0306	0.0429	CbGbCtD
Salmeterol—CYP2C8—Fosphenytoin—epilepsy syndrome	0.0288	0.0403	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Carbamazepine—epilepsy syndrome	0.0287	0.0402	CbGbCtD
Salmeterol—CYP3A7—Carbamazepine—epilepsy syndrome	0.0287	0.0402	CbGbCtD
Salmeterol—CYP3A7—Phenytoin—epilepsy syndrome	0.0257	0.036	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Phenytoin—epilepsy syndrome	0.0257	0.036	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Phenobarbital—epilepsy syndrome	0.0229	0.0321	CbGbCtD
Salmeterol—CYP3A7—Phenobarbital—epilepsy syndrome	0.0229	0.0321	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Midazolam—epilepsy syndrome	0.0226	0.0317	CbGbCtD
Salmeterol—CYP3A7—Midazolam—epilepsy syndrome	0.0226	0.0317	CbGbCtD
Salmeterol—CYP3A7—Diazepam—epilepsy syndrome	0.0217	0.0305	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Diazepam—epilepsy syndrome	0.0217	0.0305	CbGbCtD
Salmeterol—CYP3A5—Carbamazepine—epilepsy syndrome	0.0215	0.0301	CbGbCtD
Salmeterol—CYP2C8—Carbamazepine—epilepsy syndrome	0.0207	0.029	CbGbCtD
Salmeterol—CYP2C8—Primidone—epilepsy syndrome	0.0193	0.0271	CbGbCtD
Salmeterol—CYP3A5—Phenytoin—epilepsy syndrome	0.0193	0.027	CbGbCtD
Salmeterol—CYP2C8—Phenytoin—epilepsy syndrome	0.0186	0.026	CbGbCtD
Salmeterol—CYP2C8—Propofol—epilepsy syndrome	0.0173	0.0242	CbGbCtD
Salmeterol—CYP3A5—Phenobarbital—epilepsy syndrome	0.0172	0.0241	CbGbCtD
Salmeterol—CYP3A5—Midazolam—epilepsy syndrome	0.017	0.0238	CbGbCtD
Salmeterol—CYP2C8—Phenobarbital—epilepsy syndrome	0.0165	0.0232	CbGbCtD
Salmeterol—CYP3A5—Diazepam—epilepsy syndrome	0.0163	0.0228	CbGbCtD
Salmeterol—CYP2C8—Diazepam—epilepsy syndrome	0.0157	0.022	CbGbCtD
Salmeterol—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0134	0.0187	CbGbCtD
Salmeterol—CYP3A5—Valproic Acid—epilepsy syndrome	0.0129	0.018	CbGbCtD
Salmeterol—CYP3A4—Felbamate—epilepsy syndrome	0.0124	0.0174	CbGbCtD
Salmeterol—CYP3A4—Trimethadione—epilepsy syndrome	0.0124	0.0174	CbGbCtD
Salmeterol—CYP2C8—Valproic Acid—epilepsy syndrome	0.0124	0.0173	CbGbCtD
Salmeterol—CYP3A4—Fosphenytoin—epilepsy syndrome	0.0117	0.0164	CbGbCtD
Salmeterol—CYP3A4—Clonazepam—epilepsy syndrome	0.0106	0.0148	CbGbCtD
Salmeterol—CYP3A4—Clobazam—epilepsy syndrome	0.0101	0.0142	CbGbCtD
Salmeterol—CYP3A4—Rufinamide—epilepsy syndrome	0.00861	0.0121	CbGbCtD
Salmeterol—CYP3A4—Carbamazepine—epilepsy syndrome	0.00839	0.0118	CbGbCtD
Salmeterol—CYP3A4—Primidone—epilepsy syndrome	0.00784	0.011	CbGbCtD
Salmeterol—CYP3A4—Phenytoin—epilepsy syndrome	0.00753	0.0105	CbGbCtD
Salmeterol—CYP3A4—Propofol—epilepsy syndrome	0.00702	0.00983	CbGbCtD
Salmeterol—CYP3A4—Acetazolamide—epilepsy syndrome	0.00671	0.0094	CbGbCtD
Salmeterol—CYP3A4—Phenobarbital—epilepsy syndrome	0.00671	0.0094	CbGbCtD
Salmeterol—CYP3A4—Midazolam—epilepsy syndrome	0.00662	0.00927	CbGbCtD
Salmeterol—CYP3A4—Diazepam—epilepsy syndrome	0.00636	0.00891	CbGbCtD
Salmeterol—CYP3A4—Zonisamide—epilepsy syndrome	0.00621	0.0087	CbGbCtD
Salmeterol—CYP3A4—Valproic Acid—epilepsy syndrome	0.00501	0.00702	CbGbCtD
Salmeterol—CYP3A4—Topiramate—epilepsy syndrome	0.00452	0.00634	CbGbCtD
Salmeterol—Malnutrition—Gabapentin—epilepsy syndrome	8.26e-05	0.000337	CcSEcCtD
Salmeterol—Angioedema—Pregabalin—epilepsy syndrome	8.23e-05	0.000336	CcSEcCtD
Salmeterol—Hypersensitivity—Clonazepam—epilepsy syndrome	8.23e-05	0.000336	CcSEcCtD
Salmeterol—Dizziness—Vigabatrin—epilepsy syndrome	8.21e-05	0.000335	CcSEcCtD
Salmeterol—Hypersensitivity—Phenytoin—epilepsy syndrome	8.17e-05	0.000334	CcSEcCtD
Salmeterol—Oedema—Valproic Acid—epilepsy syndrome	8.13e-05	0.000332	CcSEcCtD
Salmeterol—Anaphylactic shock—Valproic Acid—epilepsy syndrome	8.13e-05	0.000332	CcSEcCtD
Salmeterol—Urticaria—Lamotrigine—epilepsy syndrome	8.13e-05	0.000332	CcSEcCtD
Salmeterol—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	8.13e-05	0.000332	CcSEcCtD
Salmeterol—Malaise—Pregabalin—epilepsy syndrome	8.12e-05	0.000332	CcSEcCtD
Salmeterol—Nausea—Propofol—epilepsy syndrome	8.12e-05	0.000331	CcSEcCtD
Salmeterol—Tension—Gabapentin—epilepsy syndrome	8.1e-05	0.000331	CcSEcCtD
Salmeterol—Vomiting—Fosphenytoin—epilepsy syndrome	8.1e-05	0.000331	CcSEcCtD
Salmeterol—Diarrhoea—Felbamate—epilepsy syndrome	8.1e-05	0.000331	CcSEcCtD
Salmeterol—Abdominal pain—Lamotrigine—epilepsy syndrome	8.09e-05	0.00033	CcSEcCtD
Salmeterol—Body temperature increased—Lamotrigine—epilepsy syndrome	8.09e-05	0.00033	CcSEcCtD
Salmeterol—Dizziness—Diazepam—epilepsy syndrome	8.09e-05	0.00033	CcSEcCtD
Salmeterol—Infection—Valproic Acid—epilepsy syndrome	8.08e-05	0.00033	CcSEcCtD
Salmeterol—Rash—Fosphenytoin—epilepsy syndrome	8.03e-05	0.000328	CcSEcCtD
Salmeterol—Dermatitis—Fosphenytoin—epilepsy syndrome	8.03e-05	0.000328	CcSEcCtD
Salmeterol—Nervousness—Gabapentin—epilepsy syndrome	8.02e-05	0.000328	CcSEcCtD
Salmeterol—Asthenia—Clonazepam—epilepsy syndrome	8.01e-05	0.000327	CcSEcCtD
Salmeterol—Rhinitis—Topiramate—epilepsy syndrome	8e-05	0.000327	CcSEcCtD
Salmeterol—Back pain—Gabapentin—epilepsy syndrome	7.99e-05	0.000326	CcSEcCtD
Salmeterol—Headache—Fosphenytoin—epilepsy syndrome	7.98e-05	0.000326	CcSEcCtD
Salmeterol—Nervous system disorder—Valproic Acid—epilepsy syndrome	7.97e-05	0.000326	CcSEcCtD
Salmeterol—Palpitations—Pregabalin—epilepsy syndrome	7.96e-05	0.000325	CcSEcCtD
Salmeterol—Asthenia—Phenytoin—epilepsy syndrome	7.96e-05	0.000325	CcSEcCtD
Salmeterol—Nausea—Midazolam—epilepsy syndrome	7.94e-05	0.000324	CcSEcCtD
Salmeterol—Muscle spasms—Gabapentin—epilepsy syndrome	7.94e-05	0.000324	CcSEcCtD
Salmeterol—Tachycardia—Valproic Acid—epilepsy syndrome	7.94e-05	0.000324	CcSEcCtD
Salmeterol—Diarrhoea—Zonisamide—epilepsy syndrome	7.93e-05	0.000324	CcSEcCtD
Salmeterol—Pharyngitis—Topiramate—epilepsy syndrome	7.92e-05	0.000323	CcSEcCtD
Salmeterol—Asthenia—Oxcarbazepine—epilepsy syndrome	7.92e-05	0.000323	CcSEcCtD
Salmeterol—Vomiting—Vigabatrin—epilepsy syndrome	7.9e-05	0.000323	CcSEcCtD
Salmeterol—Skin disorder—Valproic Acid—epilepsy syndrome	7.9e-05	0.000322	CcSEcCtD
Salmeterol—Cough—Pregabalin—epilepsy syndrome	7.86e-05	0.000321	CcSEcCtD
Salmeterol—Connective tissue disorder—Topiramate—epilepsy syndrome	7.84e-05	0.00032	CcSEcCtD
Salmeterol—Nausea—Levetiracetam—epilepsy syndrome	7.84e-05	0.00032	CcSEcCtD
Salmeterol—Rash—Vigabatrin—epilepsy syndrome	7.83e-05	0.00032	CcSEcCtD
Salmeterol—Dizziness—Felbamate—epilepsy syndrome	7.83e-05	0.00032	CcSEcCtD
Salmeterol—Dermatitis—Vigabatrin—epilepsy syndrome	7.82e-05	0.00032	CcSEcCtD
Salmeterol—Hypersensitivity—Carbamazepine—epilepsy syndrome	7.8e-05	0.000319	CcSEcCtD
Salmeterol—Headache—Vigabatrin—epilepsy syndrome	7.78e-05	0.000318	CcSEcCtD
Salmeterol—Hypertension—Pregabalin—epilepsy syndrome	7.78e-05	0.000318	CcSEcCtD
Salmeterol—Vomiting—Diazepam—epilepsy syndrome	7.78e-05	0.000318	CcSEcCtD
Salmeterol—Tremor—Gabapentin—epilepsy syndrome	7.74e-05	0.000316	CcSEcCtD
Salmeterol—Rash—Diazepam—epilepsy syndrome	7.71e-05	0.000315	CcSEcCtD
Salmeterol—Dermatitis—Diazepam—epilepsy syndrome	7.7e-05	0.000315	CcSEcCtD
Salmeterol—Chest pain—Pregabalin—epilepsy syndrome	7.67e-05	0.000313	CcSEcCtD
Salmeterol—Arthralgia—Pregabalin—epilepsy syndrome	7.67e-05	0.000313	CcSEcCtD
Salmeterol—Myalgia—Pregabalin—epilepsy syndrome	7.67e-05	0.000313	CcSEcCtD
Salmeterol—Ill-defined disorder—Gabapentin—epilepsy syndrome	7.66e-05	0.000313	CcSEcCtD
Salmeterol—Dizziness—Zonisamide—epilepsy syndrome	7.66e-05	0.000313	CcSEcCtD
Salmeterol—Headache—Diazepam—epilepsy syndrome	7.66e-05	0.000313	CcSEcCtD
Salmeterol—Anxiety—Pregabalin—epilepsy syndrome	7.64e-05	0.000312	CcSEcCtD
Salmeterol—Diarrhoea—Clonazepam—epilepsy syndrome	7.64e-05	0.000312	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	7.61e-05	0.000311	CcSEcCtD
Salmeterol—Asthenia—Carbamazepine—epilepsy syndrome	7.6e-05	0.00031	CcSEcCtD
Salmeterol—Agitation—Gabapentin—epilepsy syndrome	7.59e-05	0.00031	CcSEcCtD
Salmeterol—Diarrhoea—Phenytoin—epilepsy syndrome	7.59e-05	0.00031	CcSEcCtD
Salmeterol—Discomfort—Pregabalin—epilepsy syndrome	7.58e-05	0.000309	CcSEcCtD
Salmeterol—Nausea—Fosphenytoin—epilepsy syndrome	7.57e-05	0.000309	CcSEcCtD
Salmeterol—Diarrhoea—Oxcarbazepine—epilepsy syndrome	7.55e-05	0.000308	CcSEcCtD
Salmeterol—Angioedema—Gabapentin—epilepsy syndrome	7.55e-05	0.000308	CcSEcCtD
Salmeterol—Hypersensitivity—Lamotrigine—epilepsy syndrome	7.54e-05	0.000308	CcSEcCtD
Salmeterol—Vomiting—Felbamate—epilepsy syndrome	7.53e-05	0.000307	CcSEcCtD
Salmeterol—Dry mouth—Pregabalin—epilepsy syndrome	7.5e-05	0.000306	CcSEcCtD
Salmeterol—Rash—Felbamate—epilepsy syndrome	7.46e-05	0.000305	CcSEcCtD
Salmeterol—Dermatitis—Felbamate—epilepsy syndrome	7.46e-05	0.000304	CcSEcCtD
Salmeterol—Malaise—Gabapentin—epilepsy syndrome	7.45e-05	0.000304	CcSEcCtD
Salmeterol—Headache—Felbamate—epilepsy syndrome	7.41e-05	0.000303	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	7.41e-05	0.000302	CcSEcCtD
Salmeterol—Cardiac disorder—Topiramate—epilepsy syndrome	7.41e-05	0.000302	CcSEcCtD
Salmeterol—Dizziness—Clonazepam—epilepsy syndrome	7.38e-05	0.000302	CcSEcCtD
Salmeterol—Nausea—Vigabatrin—epilepsy syndrome	7.38e-05	0.000301	CcSEcCtD
Salmeterol—Vomiting—Zonisamide—epilepsy syndrome	7.37e-05	0.000301	CcSEcCtD
Salmeterol—Insomnia—Valproic Acid—epilepsy syndrome	7.35e-05	0.0003	CcSEcCtD
Salmeterol—Anaphylactic shock—Pregabalin—epilepsy syndrome	7.35e-05	0.0003	CcSEcCtD
Salmeterol—Oedema—Pregabalin—epilepsy syndrome	7.35e-05	0.0003	CcSEcCtD
Salmeterol—Asthenia—Lamotrigine—epilepsy syndrome	7.34e-05	0.0003	CcSEcCtD
Salmeterol—Dizziness—Phenytoin—epilepsy syndrome	7.33e-05	0.000299	CcSEcCtD
Salmeterol—Rash—Zonisamide—epilepsy syndrome	7.3e-05	0.000298	CcSEcCtD
Salmeterol—Infection—Pregabalin—epilepsy syndrome	7.3e-05	0.000298	CcSEcCtD
Salmeterol—Paraesthesia—Valproic Acid—epilepsy syndrome	7.3e-05	0.000298	CcSEcCtD
Salmeterol—Palpitations—Gabapentin—epilepsy syndrome	7.3e-05	0.000298	CcSEcCtD
Salmeterol—Dermatitis—Zonisamide—epilepsy syndrome	7.3e-05	0.000298	CcSEcCtD
Salmeterol—Dizziness—Oxcarbazepine—epilepsy syndrome	7.3e-05	0.000298	CcSEcCtD
Salmeterol—Nausea—Diazepam—epilepsy syndrome	7.26e-05	0.000297	CcSEcCtD
Salmeterol—Headache—Zonisamide—epilepsy syndrome	7.26e-05	0.000296	CcSEcCtD
Salmeterol—Labetalol—CYP2D6—epilepsy syndrome	7.25e-05	0.433	CrCbGaD
Salmeterol—Dyspnoea—Valproic Acid—epilepsy syndrome	7.25e-05	0.000296	CcSEcCtD
Salmeterol—Diarrhoea—Carbamazepine—epilepsy syndrome	7.24e-05	0.000296	CcSEcCtD
Salmeterol—Immune system disorder—Topiramate—epilepsy syndrome	7.21e-05	0.000294	CcSEcCtD
Salmeterol—Nervous system disorder—Pregabalin—epilepsy syndrome	7.21e-05	0.000294	CcSEcCtD
Salmeterol—Cough—Gabapentin—epilepsy syndrome	7.21e-05	0.000294	CcSEcCtD
Salmeterol—Mediastinal disorder—Topiramate—epilepsy syndrome	7.19e-05	0.000294	CcSEcCtD
Salmeterol—Tachycardia—Pregabalin—epilepsy syndrome	7.17e-05	0.000293	CcSEcCtD
Salmeterol—Dyspepsia—Valproic Acid—epilepsy syndrome	7.16e-05	0.000292	CcSEcCtD
Salmeterol—Skin disorder—Pregabalin—epilepsy syndrome	7.14e-05	0.000292	CcSEcCtD
Salmeterol—Hypertension—Gabapentin—epilepsy syndrome	7.13e-05	0.000291	CcSEcCtD
Salmeterol—Vomiting—Clonazepam—epilepsy syndrome	7.1e-05	0.00029	CcSEcCtD
Salmeterol—Vomiting—Phenytoin—epilepsy syndrome	7.05e-05	0.000288	CcSEcCtD
Salmeterol—Rash—Clonazepam—epilepsy syndrome	7.04e-05	0.000287	CcSEcCtD
Salmeterol—Dermatitis—Clonazepam—epilepsy syndrome	7.03e-05	0.000287	CcSEcCtD
Salmeterol—Myalgia—Gabapentin—epilepsy syndrome	7.03e-05	0.000287	CcSEcCtD
Salmeterol—Arthralgia—Gabapentin—epilepsy syndrome	7.03e-05	0.000287	CcSEcCtD
Salmeterol—Chest pain—Gabapentin—epilepsy syndrome	7.03e-05	0.000287	CcSEcCtD
Salmeterol—Nausea—Felbamate—epilepsy syndrome	7.03e-05	0.000287	CcSEcCtD
Salmeterol—Vomiting—Oxcarbazepine—epilepsy syndrome	7.01e-05	0.000286	CcSEcCtD
Salmeterol—Fatigue—Valproic Acid—epilepsy syndrome	7.01e-05	0.000286	CcSEcCtD
Salmeterol—Anxiety—Gabapentin—epilepsy syndrome	7.01e-05	0.000286	CcSEcCtD
Salmeterol—Dizziness—Carbamazepine—epilepsy syndrome	7e-05	0.000286	CcSEcCtD
Salmeterol—Diarrhoea—Lamotrigine—epilepsy syndrome	7e-05	0.000286	CcSEcCtD
Salmeterol—Headache—Clonazepam—epilepsy syndrome	6.99e-05	0.000286	CcSEcCtD
Salmeterol—Rash—Phenytoin—epilepsy syndrome	6.99e-05	0.000286	CcSEcCtD
Salmeterol—Mental disorder—Topiramate—epilepsy syndrome	6.99e-05	0.000286	CcSEcCtD
Salmeterol—Dermatitis—Phenytoin—epilepsy syndrome	6.99e-05	0.000285	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	6.98e-05	0.000285	CcSEcCtD
Salmeterol—Rash—Oxcarbazepine—epilepsy syndrome	6.96e-05	0.000284	CcSEcCtD
Salmeterol—Pain—Valproic Acid—epilepsy syndrome	6.95e-05	0.000284	CcSEcCtD
Salmeterol—Constipation—Valproic Acid—epilepsy syndrome	6.95e-05	0.000284	CcSEcCtD
Salmeterol—Dermatitis—Oxcarbazepine—epilepsy syndrome	6.95e-05	0.000284	CcSEcCtD
Salmeterol—Headache—Phenytoin—epilepsy syndrome	6.95e-05	0.000284	CcSEcCtD
Salmeterol—Malnutrition—Topiramate—epilepsy syndrome	6.95e-05	0.000284	CcSEcCtD
Salmeterol—Discomfort—Gabapentin—epilepsy syndrome	6.95e-05	0.000284	CcSEcCtD
Salmeterol—Headache—Oxcarbazepine—epilepsy syndrome	6.91e-05	0.000282	CcSEcCtD
Salmeterol—Nausea—Zonisamide—epilepsy syndrome	6.88e-05	0.000281	CcSEcCtD
Salmeterol—Dry mouth—Gabapentin—epilepsy syndrome	6.88e-05	0.000281	CcSEcCtD
Salmeterol—Tension—Topiramate—epilepsy syndrome	6.82e-05	0.000278	CcSEcCtD
Salmeterol—Dizziness—Lamotrigine—epilepsy syndrome	6.77e-05	0.000276	CcSEcCtD
Salmeterol—Nervousness—Topiramate—epilepsy syndrome	6.75e-05	0.000276	CcSEcCtD
Salmeterol—Anaphylactic shock—Gabapentin—epilepsy syndrome	6.74e-05	0.000275	CcSEcCtD
Salmeterol—Oedema—Gabapentin—epilepsy syndrome	6.74e-05	0.000275	CcSEcCtD
Salmeterol—Vomiting—Carbamazepine—epilepsy syndrome	6.73e-05	0.000275	CcSEcCtD
Salmeterol—Back pain—Topiramate—epilepsy syndrome	6.72e-05	0.000274	CcSEcCtD
Salmeterol—Feeling abnormal—Valproic Acid—epilepsy syndrome	6.7e-05	0.000274	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	6.7e-05	0.000273	CcSEcCtD
Salmeterol—Infection—Gabapentin—epilepsy syndrome	6.7e-05	0.000273	CcSEcCtD
Salmeterol—Muscle spasms—Topiramate—epilepsy syndrome	6.68e-05	0.000273	CcSEcCtD
Salmeterol—Rash—Carbamazepine—epilepsy syndrome	6.68e-05	0.000273	CcSEcCtD
Salmeterol—Dermatitis—Carbamazepine—epilepsy syndrome	6.67e-05	0.000272	CcSEcCtD
Salmeterol—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	6.65e-05	0.000271	CcSEcCtD
Salmeterol—Insomnia—Pregabalin—epilepsy syndrome	6.65e-05	0.000271	CcSEcCtD
Salmeterol—Nausea—Clonazepam—epilepsy syndrome	6.63e-05	0.000271	CcSEcCtD
Salmeterol—Headache—Carbamazepine—epilepsy syndrome	6.63e-05	0.000271	CcSEcCtD
Salmeterol—Nervous system disorder—Gabapentin—epilepsy syndrome	6.61e-05	0.00027	CcSEcCtD
Salmeterol—Paraesthesia—Pregabalin—epilepsy syndrome	6.6e-05	0.00027	CcSEcCtD
Salmeterol—Nausea—Phenytoin—epilepsy syndrome	6.59e-05	0.000269	CcSEcCtD
Salmeterol—Tachycardia—Gabapentin—epilepsy syndrome	6.58e-05	0.000269	CcSEcCtD
Salmeterol—Dyspnoea—Pregabalin—epilepsy syndrome	6.55e-05	0.000268	CcSEcCtD
Salmeterol—Nausea—Oxcarbazepine—epilepsy syndrome	6.55e-05	0.000268	CcSEcCtD
Salmeterol—Skin disorder—Gabapentin—epilepsy syndrome	6.55e-05	0.000267	CcSEcCtD
Salmeterol—Tremor—Topiramate—epilepsy syndrome	6.51e-05	0.000266	CcSEcCtD
Salmeterol—Vomiting—Lamotrigine—epilepsy syndrome	6.51e-05	0.000266	CcSEcCtD
Salmeterol—Urticaria—Valproic Acid—epilepsy syndrome	6.46e-05	0.000264	CcSEcCtD
Salmeterol—Rash—Lamotrigine—epilepsy syndrome	6.45e-05	0.000263	CcSEcCtD
Salmeterol—Ill-defined disorder—Topiramate—epilepsy syndrome	6.45e-05	0.000263	CcSEcCtD
Salmeterol—Dermatitis—Lamotrigine—epilepsy syndrome	6.45e-05	0.000263	CcSEcCtD
Salmeterol—Body temperature increased—Valproic Acid—epilepsy syndrome	6.43e-05	0.000262	CcSEcCtD
Salmeterol—Abdominal pain—Valproic Acid—epilepsy syndrome	6.43e-05	0.000262	CcSEcCtD
Salmeterol—Headache—Lamotrigine—epilepsy syndrome	6.41e-05	0.000262	CcSEcCtD
Salmeterol—Agitation—Topiramate—epilepsy syndrome	6.39e-05	0.000261	CcSEcCtD
Salmeterol—Fatigue—Pregabalin—epilepsy syndrome	6.34e-05	0.000259	CcSEcCtD
Salmeterol—Nausea—Carbamazepine—epilepsy syndrome	6.29e-05	0.000257	CcSEcCtD
Salmeterol—Pain—Pregabalin—epilepsy syndrome	6.29e-05	0.000257	CcSEcCtD
Salmeterol—Constipation—Pregabalin—epilepsy syndrome	6.29e-05	0.000257	CcSEcCtD
Salmeterol—Malaise—Topiramate—epilepsy syndrome	6.27e-05	0.000256	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	6.14e-05	0.000251	CcSEcCtD
Salmeterol—Palpitations—Topiramate—epilepsy syndrome	6.14e-05	0.000251	CcSEcCtD
Salmeterol—Insomnia—Gabapentin—epilepsy syndrome	6.1e-05	0.000249	CcSEcCtD
Salmeterol—Nausea—Lamotrigine—epilepsy syndrome	6.08e-05	0.000248	CcSEcCtD
Salmeterol—Cough—Topiramate—epilepsy syndrome	6.06e-05	0.000248	CcSEcCtD
Salmeterol—Feeling abnormal—Pregabalin—epilepsy syndrome	6.06e-05	0.000247	CcSEcCtD
Salmeterol—Paraesthesia—Gabapentin—epilepsy syndrome	6.05e-05	0.000247	CcSEcCtD
Salmeterol—Gastrointestinal pain—Pregabalin—epilepsy syndrome	6.01e-05	0.000245	CcSEcCtD
Salmeterol—Dyspnoea—Gabapentin—epilepsy syndrome	6.01e-05	0.000245	CcSEcCtD
Salmeterol—Hypertension—Topiramate—epilepsy syndrome	6e-05	0.000245	CcSEcCtD
Salmeterol—Hypersensitivity—Valproic Acid—epilepsy syndrome	5.99e-05	0.000245	CcSEcCtD
Salmeterol—Dyspepsia—Gabapentin—epilepsy syndrome	5.93e-05	0.000242	CcSEcCtD
Salmeterol—Myalgia—Topiramate—epilepsy syndrome	5.92e-05	0.000242	CcSEcCtD
Salmeterol—Chest pain—Topiramate—epilepsy syndrome	5.92e-05	0.000242	CcSEcCtD
Salmeterol—Arthralgia—Topiramate—epilepsy syndrome	5.92e-05	0.000242	CcSEcCtD
Salmeterol—Anxiety—Topiramate—epilepsy syndrome	5.89e-05	0.000241	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	5.87e-05	0.00024	CcSEcCtD
Salmeterol—Discomfort—Topiramate—epilepsy syndrome	5.84e-05	0.000239	CcSEcCtD
Salmeterol—Urticaria—Pregabalin—epilepsy syndrome	5.84e-05	0.000238	CcSEcCtD
Salmeterol—Asthenia—Valproic Acid—epilepsy syndrome	5.83e-05	0.000238	CcSEcCtD
Salmeterol—Fatigue—Gabapentin—epilepsy syndrome	5.81e-05	0.000237	CcSEcCtD
Salmeterol—Abdominal pain—Pregabalin—epilepsy syndrome	5.81e-05	0.000237	CcSEcCtD
Salmeterol—Body temperature increased—Pregabalin—epilepsy syndrome	5.81e-05	0.000237	CcSEcCtD
Salmeterol—Dry mouth—Topiramate—epilepsy syndrome	5.79e-05	0.000236	CcSEcCtD
Salmeterol—Constipation—Gabapentin—epilepsy syndrome	5.76e-05	0.000235	CcSEcCtD
Salmeterol—Pain—Gabapentin—epilepsy syndrome	5.76e-05	0.000235	CcSEcCtD
Salmeterol—Oedema—Topiramate—epilepsy syndrome	5.67e-05	0.000232	CcSEcCtD
Salmeterol—Infection—Topiramate—epilepsy syndrome	5.63e-05	0.00023	CcSEcCtD
Salmeterol—Diarrhoea—Valproic Acid—epilepsy syndrome	5.56e-05	0.000227	CcSEcCtD
Salmeterol—Nervous system disorder—Topiramate—epilepsy syndrome	5.56e-05	0.000227	CcSEcCtD
Salmeterol—Feeling abnormal—Gabapentin—epilepsy syndrome	5.55e-05	0.000227	CcSEcCtD
Salmeterol—Propafenone—CYP2D6—epilepsy syndrome	5.55e-05	0.331	CrCbGaD
Salmeterol—Tachycardia—Topiramate—epilepsy syndrome	5.53e-05	0.000226	CcSEcCtD
Salmeterol—Gastrointestinal pain—Gabapentin—epilepsy syndrome	5.51e-05	0.000225	CcSEcCtD
Salmeterol—Skin disorder—Topiramate—epilepsy syndrome	5.51e-05	0.000225	CcSEcCtD
Salmeterol—Hypersensitivity—Pregabalin—epilepsy syndrome	5.42e-05	0.000221	CcSEcCtD
Salmeterol—Dizziness—Valproic Acid—epilepsy syndrome	5.38e-05	0.00022	CcSEcCtD
Salmeterol—Urticaria—Gabapentin—epilepsy syndrome	5.35e-05	0.000219	CcSEcCtD
Salmeterol—Body temperature increased—Gabapentin—epilepsy syndrome	5.33e-05	0.000218	CcSEcCtD
Salmeterol—Abdominal pain—Gabapentin—epilepsy syndrome	5.33e-05	0.000218	CcSEcCtD
Salmeterol—Asthenia—Pregabalin—epilepsy syndrome	5.27e-05	0.000215	CcSEcCtD
Salmeterol—Vomiting—Valproic Acid—epilepsy syndrome	5.17e-05	0.000211	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	5.17e-05	0.000211	CcSEcCtD
Salmeterol—Insomnia—Topiramate—epilepsy syndrome	5.13e-05	0.000209	CcSEcCtD
Salmeterol—Rash—Valproic Acid—epilepsy syndrome	5.13e-05	0.000209	CcSEcCtD
Salmeterol—Dermatitis—Valproic Acid—epilepsy syndrome	5.12e-05	0.000209	CcSEcCtD
Salmeterol—Headache—Valproic Acid—epilepsy syndrome	5.09e-05	0.000208	CcSEcCtD
Salmeterol—Paraesthesia—Topiramate—epilepsy syndrome	5.09e-05	0.000208	CcSEcCtD
Salmeterol—Dyspnoea—Topiramate—epilepsy syndrome	5.06e-05	0.000206	CcSEcCtD
Salmeterol—Diarrhoea—Pregabalin—epilepsy syndrome	5.03e-05	0.000205	CcSEcCtD
Salmeterol—Dyspepsia—Topiramate—epilepsy syndrome	4.99e-05	0.000204	CcSEcCtD
Salmeterol—Hypersensitivity—Gabapentin—epilepsy syndrome	4.97e-05	0.000203	CcSEcCtD
Salmeterol—Fatigue—Topiramate—epilepsy syndrome	4.89e-05	0.0002	CcSEcCtD
Salmeterol—Dizziness—Pregabalin—epilepsy syndrome	4.86e-05	0.000198	CcSEcCtD
Salmeterol—Pain—Topiramate—epilepsy syndrome	4.85e-05	0.000198	CcSEcCtD
Salmeterol—Constipation—Topiramate—epilepsy syndrome	4.85e-05	0.000198	CcSEcCtD
Salmeterol—Asthenia—Gabapentin—epilepsy syndrome	4.84e-05	0.000197	CcSEcCtD
Salmeterol—Nausea—Valproic Acid—epilepsy syndrome	4.83e-05	0.000197	CcSEcCtD
Salmeterol—Vomiting—Pregabalin—epilepsy syndrome	4.67e-05	0.000191	CcSEcCtD
Salmeterol—Feeling abnormal—Topiramate—epilepsy syndrome	4.67e-05	0.000191	CcSEcCtD
Salmeterol—Gastrointestinal pain—Topiramate—epilepsy syndrome	4.64e-05	0.000189	CcSEcCtD
Salmeterol—Rash—Pregabalin—epilepsy syndrome	4.63e-05	0.000189	CcSEcCtD
Salmeterol—Dermatitis—Pregabalin—epilepsy syndrome	4.63e-05	0.000189	CcSEcCtD
Salmeterol—Diarrhoea—Gabapentin—epilepsy syndrome	4.61e-05	0.000188	CcSEcCtD
Salmeterol—Headache—Pregabalin—epilepsy syndrome	4.6e-05	0.000188	CcSEcCtD
Salmeterol—Urticaria—Topiramate—epilepsy syndrome	4.5e-05	0.000184	CcSEcCtD
Salmeterol—Abdominal pain—Topiramate—epilepsy syndrome	4.48e-05	0.000183	CcSEcCtD
Salmeterol—Body temperature increased—Topiramate—epilepsy syndrome	4.48e-05	0.000183	CcSEcCtD
Salmeterol—Dizziness—Gabapentin—epilepsy syndrome	4.46e-05	0.000182	CcSEcCtD
Salmeterol—Nausea—Pregabalin—epilepsy syndrome	4.37e-05	0.000178	CcSEcCtD
Salmeterol—Vomiting—Gabapentin—epilepsy syndrome	4.29e-05	0.000175	CcSEcCtD
Salmeterol—Rash—Gabapentin—epilepsy syndrome	4.25e-05	0.000174	CcSEcCtD
Salmeterol—Dermatitis—Gabapentin—epilepsy syndrome	4.25e-05	0.000173	CcSEcCtD
Salmeterol—Headache—Gabapentin—epilepsy syndrome	4.22e-05	0.000172	CcSEcCtD
Salmeterol—Hypersensitivity—Topiramate—epilepsy syndrome	4.18e-05	0.000171	CcSEcCtD
Salmeterol—Asthenia—Topiramate—epilepsy syndrome	4.07e-05	0.000166	CcSEcCtD
Salmeterol—Nausea—Gabapentin—epilepsy syndrome	4e-05	0.000163	CcSEcCtD
Salmeterol—Propafenone—ABCB1—epilepsy syndrome	3.96e-05	0.236	CrCbGaD
Salmeterol—Diarrhoea—Topiramate—epilepsy syndrome	3.88e-05	0.000158	CcSEcCtD
Salmeterol—Dizziness—Topiramate—epilepsy syndrome	3.75e-05	0.000153	CcSEcCtD
Salmeterol—Vomiting—Topiramate—epilepsy syndrome	3.61e-05	0.000147	CcSEcCtD
Salmeterol—Rash—Topiramate—epilepsy syndrome	3.58e-05	0.000146	CcSEcCtD
Salmeterol—Dermatitis—Topiramate—epilepsy syndrome	3.57e-05	0.000146	CcSEcCtD
Salmeterol—Headache—Topiramate—epilepsy syndrome	3.55e-05	0.000145	CcSEcCtD
Salmeterol—Nausea—Topiramate—epilepsy syndrome	3.37e-05	0.000138	CcSEcCtD
Salmeterol—ADRB2—GPCR downstream signaling—HTR7—epilepsy syndrome	1.72e-05	0.000421	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—POMC—epilepsy syndrome	1.71e-05	0.000417	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADRA2A—epilepsy syndrome	1.7e-05	0.000416	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GBE1—epilepsy syndrome	1.68e-05	0.00041	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPP1R3C—epilepsy syndrome	1.68e-05	0.00041	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CCL2—epilepsy syndrome	1.67e-05	0.000408	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—OPRD1—epilepsy syndrome	1.66e-05	0.000406	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GNAO1—epilepsy syndrome	1.66e-05	0.000406	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CACNA1A—epilepsy syndrome	1.65e-05	0.000403	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALDH7A1—epilepsy syndrome	1.65e-05	0.000403	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT3—epilepsy syndrome	1.64e-05	0.000402	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	1.64e-05	0.000401	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL12—epilepsy syndrome	1.63e-05	0.0004	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—BDKRB2—epilepsy syndrome	1.63e-05	0.0004	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ST3GAL3—epilepsy syndrome	1.61e-05	0.000394	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CNR1—epilepsy syndrome	1.6e-05	0.000392	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PLCB1—epilepsy syndrome	1.6e-05	0.000391	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCR7—epilepsy syndrome	1.59e-05	0.00039	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GRM1—epilepsy syndrome	1.59e-05	0.00039	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDYN—epilepsy syndrome	1.59e-05	0.00039	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CHRM1—epilepsy syndrome	1.59e-05	0.00039	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADSL—epilepsy syndrome	1.58e-05	0.000386	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ASAH1—epilepsy syndrome	1.58e-05	0.000386	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HTR7—epilepsy syndrome	1.57e-05	0.000383	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GLUL—epilepsy syndrome	1.55e-05	0.000378	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—STXBP1—epilepsy syndrome	1.53e-05	0.000375	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CACNA1D—epilepsy syndrome	1.52e-05	0.000371	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HBEGF—epilepsy syndrome	1.52e-05	0.000371	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CDC42—epilepsy syndrome	1.5e-05	0.000366	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GAL—epilepsy syndrome	1.5e-05	0.000366	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GFAP—epilepsy syndrome	1.5e-05	0.000366	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NT5E—epilepsy syndrome	1.49e-05	0.000365	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALAD—epilepsy syndrome	1.49e-05	0.000365	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT3—epilepsy syndrome	1.49e-05	0.000365	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP2—epilepsy syndrome	1.48e-05	0.000362	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CHRM3—epilepsy syndrome	1.48e-05	0.000362	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GRM5—epilepsy syndrome	1.48e-05	0.000362	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AVP—epilepsy syndrome	1.45e-05	0.000355	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CACNA1A—epilepsy syndrome	1.43e-05	0.000349	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALDH7A1—epilepsy syndrome	1.43e-05	0.000349	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TXNRD1—epilepsy syndrome	1.42e-05	0.000347	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CX3CR1—epilepsy syndrome	1.42e-05	0.000347	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ABCG2—epilepsy syndrome	1.41e-05	0.000344	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADK—epilepsy syndrome	1.4e-05	0.000342	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—L2HGDH—epilepsy syndrome	1.4e-05	0.000342	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CERS1—epilepsy syndrome	1.4e-05	0.000342	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PDXK—epilepsy syndrome	1.4e-05	0.000342	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GLUD1—epilepsy syndrome	1.4e-05	0.000342	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—FAR1—epilepsy syndrome	1.4e-05	0.000342	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ST3GAL3—epilepsy syndrome	1.4e-05	0.000341	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CX3CL1—epilepsy syndrome	1.39e-05	0.000341	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CHRM2—epilepsy syndrome	1.39e-05	0.000341	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BDKRB1—epilepsy syndrome	1.39e-05	0.000341	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AQP1—epilepsy syndrome	1.38e-05	0.000337	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2C19—epilepsy syndrome	1.37e-05	0.000335	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADSL—epilepsy syndrome	1.37e-05	0.000334	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP11A1—epilepsy syndrome	1.36e-05	0.000333	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CDC42—epilepsy syndrome	1.36e-05	0.000333	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GABBR1—epilepsy syndrome	1.35e-05	0.000331	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GLUL—epilepsy syndrome	1.34e-05	0.000328	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AVP—epilepsy syndrome	1.32e-05	0.000322	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CACNA1D—epilepsy syndrome	1.32e-05	0.000322	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HRH3—epilepsy syndrome	1.3e-05	0.000318	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—OPRM1—epilepsy syndrome	1.28e-05	0.000313	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PNPO—epilepsy syndrome	1.28e-05	0.000312	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—EPM2A—epilepsy syndrome	1.28e-05	0.000312	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GAMT—epilepsy syndrome	1.28e-05	0.000312	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NHLRC1—epilepsy syndrome	1.28e-05	0.000312	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—KCNJ11—epilepsy syndrome	1.25e-05	0.000305	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CHRM3—epilepsy syndrome	1.25e-05	0.000305	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CCR5—epilepsy syndrome	1.23e-05	0.000302	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TXNRD1—epilepsy syndrome	1.23e-05	0.000301	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2D6—epilepsy syndrome	1.23e-05	0.000301	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCR3—epilepsy syndrome	1.21e-05	0.000295	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—HTR2A—epilepsy syndrome	1.21e-05	0.000295	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AQP1—epilepsy syndrome	1.2e-05	0.000292	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CA4—epilepsy syndrome	1.19e-05	0.00029	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—QDPR—epilepsy syndrome	1.19e-05	0.00029	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	1.18e-05	0.000289	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NPY—epilepsy syndrome	1.18e-05	0.000288	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ATP2A2—epilepsy syndrome	1.18e-05	0.000288	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ADRA2A—epilepsy syndrome	1.17e-05	0.000286	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—BCHE—epilepsy syndrome	1.17e-05	0.000285	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	1.15e-05	0.000281	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AGT—epilepsy syndrome	1.15e-05	0.00028	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—OXT—epilepsy syndrome	1.14e-05	0.000278	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CRH—epilepsy syndrome	1.14e-05	0.000278	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCL3—epilepsy syndrome	1.14e-05	0.000278	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL2—epilepsy syndrome	1.14e-05	0.000278	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HSPB1—epilepsy syndrome	1.14e-05	0.000278	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CCR5—epilepsy syndrome	1.12e-05	0.000274	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—COX3—epilepsy syndrome	1.12e-05	0.000273	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SLC2A1—epilepsy syndrome	1.11e-05	0.000272	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PLCB1—epilepsy syndrome	1.1e-05	0.000269	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TH—epilepsy syndrome	1.1e-05	0.000268	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HTR2A—epilepsy syndrome	1.1e-05	0.000268	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—KCNJ11—epilepsy syndrome	1.08e-05	0.000264	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CHRM3—epilepsy syndrome	1.08e-05	0.000264	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PFKL—epilepsy syndrome	1.06e-05	0.000259	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	1.06e-05	0.000259	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	1.06e-05	0.000259	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	1.06e-05	0.000259	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	1.06e-05	0.000259	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.06e-05	0.000259	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTK2B—epilepsy syndrome	1.06e-05	0.000258	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TSC1—epilepsy syndrome	1.06e-05	0.000258	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AGT—epilepsy syndrome	1.04e-05	0.000254	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SST—epilepsy syndrome	1.03e-05	0.000251	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NTRK2—epilepsy syndrome	1.03e-05	0.000251	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCR2—epilepsy syndrome	1.03e-05	0.000251	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DUSP6—epilepsy syndrome	1.02e-05	0.000249	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCG2—epilepsy syndrome	1.02e-05	0.000249	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.01e-05	0.000246	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADRA2A—epilepsy syndrome	1e-05	0.000246	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PLAT—epilepsy syndrome	1e-05	0.000245	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2C19—epilepsy syndrome	9.91e-06	0.000242	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	9.86e-06	0.000241	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP11A1—epilepsy syndrome	9.85e-06	0.000241	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NEU1—epilepsy syndrome	9.68e-06	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ATIC—epilepsy syndrome	9.68e-06	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UPB1—epilepsy syndrome	9.68e-06	0.000237	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BDKRB2—epilepsy syndrome	9.65e-06	0.000236	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL12—epilepsy syndrome	9.65e-06	0.000236	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—POMC—epilepsy syndrome	9.64e-06	0.000236	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PRKCB—epilepsy syndrome	9.61e-06	0.000235	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6ST—epilepsy syndrome	9.57e-06	0.000234	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CNR1—epilepsy syndrome	9.48e-06	0.000232	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JUNB—epilepsy syndrome	9.48e-06	0.000232	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PLCB1—epilepsy syndrome	9.44e-06	0.000231	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	9.32e-06	0.000228	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HTR7—epilepsy syndrome	9.25e-06	0.000226	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HMOX1—epilepsy syndrome	9.15e-06	0.000224	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAT—epilepsy syndrome	9.03e-06	0.000221	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GBE1—epilepsy syndrome	9e-06	0.00022	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	9e-06	0.00022	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HBEGF—epilepsy syndrome	8.98e-06	0.000219	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2D6—epilepsy syndrome	8.89e-06	0.000217	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCG2—epilepsy syndrome	8.81e-06	0.000215	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT3—epilepsy syndrome	8.81e-06	0.000215	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ABCB1—epilepsy syndrome	8.78e-06	0.000215	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—POMC—epilepsy syndrome	8.75e-06	0.000214	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADAM10—epilepsy syndrome	8.61e-06	0.00021	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2C19—epilepsy syndrome	8.59e-06	0.00021	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CCL2—epilepsy syndrome	8.57e-06	0.000209	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP11A1—epilepsy syndrome	8.53e-06	0.000209	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	8.47e-06	0.000207	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	8.46e-06	0.000207	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADRA2A—epilepsy syndrome	8.46e-06	0.000207	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—BCHE—epilepsy syndrome	8.43e-06	0.000206	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	8.23e-06	0.000201	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GPX1—epilepsy syndrome	8.16e-06	0.0002	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—S100B—epilepsy syndrome	8.14e-06	0.000199	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SOCS3—epilepsy syndrome	8.06e-06	0.000197	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC2A1—epilepsy syndrome	8.04e-06	0.000197	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDC42—epilepsy syndrome	8.04e-06	0.000197	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALAD—epilepsy syndrome	8.02e-06	0.000196	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NT5E—epilepsy syndrome	8.02e-06	0.000196	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PLCB1—epilepsy syndrome	7.95e-06	0.000194	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TH—epilepsy syndrome	7.92e-06	0.000194	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AVP—epilepsy syndrome	7.78e-06	0.00019	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	7.72e-06	0.000189	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2D6—epilepsy syndrome	7.7e-06	0.000188	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	7.65e-06	0.000187	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	7.65e-06	0.000187	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	7.49e-06	0.000183	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HES1—epilepsy syndrome	7.36e-06	0.00018	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADSL—epilepsy syndrome	7.34e-06	0.000179	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADRA2A—epilepsy syndrome	7.33e-06	0.000179	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—BCHE—epilepsy syndrome	7.3e-06	0.000178	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GLUL—epilepsy syndrome	7.2e-06	0.000176	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AGT—epilepsy syndrome	7.16e-06	0.000175	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FYN—epilepsy syndrome	7.16e-06	0.000175	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—H2AFX—epilepsy syndrome	7.13e-06	0.000174	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MEF2C—epilepsy syndrome	7.12e-06	0.000174	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	7.06e-06	0.000173	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOE—epilepsy syndrome	7.01e-06	0.000171	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	6.96e-06	0.00017	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	6.89e-06	0.000168	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—YWHAZ—epilepsy syndrome	6.88e-06	0.000168	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TH—epilepsy syndrome	6.86e-06	0.000168	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NGF—epilepsy syndrome	6.8e-06	0.000166	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	6.76e-06	0.000165	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCR5—epilepsy syndrome	6.62e-06	0.000162	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	6.61e-06	0.000162	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	6.61e-06	0.000162	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAT—epilepsy syndrome	6.53e-06	0.00016	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HTR2A—epilepsy syndrome	6.48e-06	0.000158	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AQP1—epilepsy syndrome	6.41e-06	0.000157	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	6.35e-06	0.000155	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TSC2—epilepsy syndrome	6.15e-06	0.00015	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AGT—epilepsy syndrome	6.14e-06	0.00015	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—POMC—epilepsy syndrome	6.03e-06	0.000147	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOE—epilepsy syndrome	6.02e-06	0.000147	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GPX1—epilepsy syndrome	5.9e-06	0.000144	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KDR—epilepsy syndrome	5.9e-06	0.000144	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	5.8e-06	0.000142	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	5.8e-06	0.000142	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	5.73e-06	0.00014	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PRKCB—epilepsy syndrome	5.68e-06	0.000139	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6ST—epilepsy syndrome	5.65e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAT—epilepsy syndrome	5.65e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	5.5e-06	0.000134	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALB—epilepsy syndrome	5.49e-06	0.000134	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AGT—epilepsy syndrome	5.17e-06	0.000127	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—POMC—epilepsy syndrome	5.17e-06	0.000126	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GPX1—epilepsy syndrome	5.11e-06	0.000125	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOE—epilepsy syndrome	5.07e-06	0.000124	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCL2—epilepsy syndrome	5.06e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—epilepsy syndrome	4.81e-06	0.000118	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	4.73e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	4.61e-06	0.000113	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	4.58e-06	0.000112	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF2—epilepsy syndrome	4.57e-06	0.000112	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AGT—epilepsy syndrome	4.48e-06	0.00011	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOE—epilepsy syndrome	4.39e-06	0.000107	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—POMC—epilepsy syndrome	4.36e-06	0.000106	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RELA—epilepsy syndrome	4.25e-06	0.000104	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MTOR—epilepsy syndrome	4.16e-06	0.000102	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	4.13e-06	0.000101	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALB—epilepsy syndrome	3.97e-06	9.71e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	3.93e-06	9.62e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BCHE—epilepsy syndrome	3.92e-06	9.58e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—epilepsy syndrome	3.86e-06	9.45e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP3—epilepsy syndrome	3.83e-06	9.36e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—POMC—epilepsy syndrome	3.77e-06	9.22e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	3.74e-06	9.14e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JUN—epilepsy syndrome	3.72e-06	9.09e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	3.7e-06	9.04e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TH—epilepsy syndrome	3.68e-06	9.01e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—epilepsy syndrome	3.62e-06	8.85e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—epilepsy syndrome	3.51e-06	8.58e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	3.47e-06	8.49e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALB—epilepsy syndrome	3.44e-06	8.41e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SRC—epilepsy syndrome	3.34e-06	8.16e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—epilepsy syndrome	3.25e-06	7.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	3.07e-06	7.52e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAT—epilepsy syndrome	3.03e-06	7.42e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	3.01e-06	7.36e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	2.95e-06	7.22e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPX1—epilepsy syndrome	2.74e-06	6.71e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—epilepsy syndrome	2.42e-06	5.91e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AGT—epilepsy syndrome	2.41e-06	5.88e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOE—epilepsy syndrome	2.36e-06	5.76e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—epilepsy syndrome	2.07e-06	5.07e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—POMC—epilepsy syndrome	2.03e-06	4.95e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALB—epilepsy syndrome	1.85e-06	4.51e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—epilepsy syndrome	1.75e-06	4.27e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.62e-06	3.95e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—epilepsy syndrome	1.51e-06	3.7e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—epilepsy syndrome	8.12e-07	1.98e-05	CbGpPWpGaD
